News Portal

trader32176
Posts: 3903
Joined: Fri Jun 26, 2020 5:22 am
Location: the trenches

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Successfully Treats “No Option” Patients with its JadiCell Stem Cell Therapy While Advancing Preparations for Phase III COVID-19 Clinical Trial

Company Accelerating Clinical Progress in Response to Omicron Outbreak by Pre-Trial Implementation in “Real Life” Clinical Situations Leveraging Right to Try Exemption


December 30, 2021 10:00 AM Eastern Standard Time

https://www.businesswire.com/news/home/ ... ical-Trial


OCEANSIDE, Calif.--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today successful treatment of 15 recent patients under the Right to Try Law with the Company’s universal donor JadiCell™ adult stem cell product. All patients displayed no adverse events and demonstrated subjective and objective levels of improvement.

There were 12 COVID-19 patients who underwent a profound recovery despite advanced stage of disease, while the retired Navy SEAL that was previously publicly disclosed1 along with two other retired SEALS, had a significant decrease in biomarkers associated with Chronic Traumatic Encephalopathy (CTE), as well as psychological improvement at the two month follow up.

“We are making progress in preparing for the upcoming Phase III clinical trial of JadiCells for treatment of COVID-19. This includes negotiation with the contract research organization, site recruitment and selection, as well as organization of trial logistics,” said James Veltmeyer, Chief Medical Officer of the Company. “Despite this, COVID-19 and variants of concern such as omicron, have the potential to wreak severe chaos on our healthcare system. We have literally saved lives with JadiCells and believe in making the treatment available as soon as possible under appropriate conditions.”

Under the Right to Try Law, companies are allowed to provide experimental therapies that have passed Phase I clinical trials to patients who in the opinion of the physician have no therapeutic options available to them.

“We plan to continue clinical implementation and data collection in a real time setting using JadiCells for patients whose physicians deem they qualify under Right to Try,” said Timothy Dixon, President and CEO of Therapeutic Solutions International. “Nothing makes me feel better as CEO of this Company than seeing firsthand our product saving lives. Now the mission is to make it available on a large scale, which we will.”

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/.

1 Therapeutic Solutions International Successfully Treats Veteran Navy SEAL Suffering from Chronic Traumatic Encephalopathy with JadiCell™ Adult Stem Cells Under Right to Try Law
trader32176
Posts: 3903
Joined: Fri Jun 26, 2020 5:22 am
Location: the trenches

Re: News Portal

Post by trader32176 »

NEWS 1/3/22
Therapeutic Solutions International Reports Positive Clinical Data on QuadraMune® Reduction of SARS-CoV-2 Spike Protein Induced Inflammation
Clinical Study Shows 7 Day Course of QuadraMune® Reduces COVID-19 Hyperinflammation Induced by Monocytes

https://www.businesswire.com/news/home/ ... flammation

Therapeutic Solutions International Reports Positive Clinical Data on QuadraMune® Reduction of SARS-CoV-2 Spike Protein Induced Inflammation
Clinical Study Shows 7 Day Course of QuadraMune® Reduces COVID-19 Hyperinflammation Induced by Monocytes

OCEANSIDE, Calif.--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today positive results of a pilot clinical trial in 20 subjects.

“QuadraMune is a unique nutraceutical supplement that suppresses inflammatory pathways associated with COVID-19 mortality, while at the same time inhibits immune suppressive enzymes such as indolamine 2,3 dioxygenase”

“QuadraMune is a unique nutraceutical supplement that suppresses inflammatory pathways associated with COVID-19 mortality, while at the same time inhibits immune suppressive enzymes such as indolamine 2,3 dioxygenase,” said Dr. Thomas Ichim, co-inventor of QuadraMune and Board Member of the Company. “As new variants of concern keep emerging, we believe it is necessary to continue exploring various immune modulatory strategies that potentially synergize with existing vaccination efforts.”

Last week Therapeutic Solutions International received a notice of allowance granting a patent on the immune modulatory and COVID-19 inhibiting properties of QuadraMune1.

“In addition to studies performed by us and our collaborators, independent groups have published in the peer-reviewed literature that ingredients of QuadraMune possess activity against SARS-CoV-2 which are discussed in this press release2,” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “We are currently working with numerous colleagues to collect clinical and laboratory data to optimize dosing and ideal combination therapies.”

“As a Company we pride ourselves in continually seeking to understand the mechanisms of action of our products,” said Timothy Dixon, President and CEO of TSOI and co-inventor of QuadraMune. “To our knowledge this is the only nutraceutical that actually alters immune cells of patients in order to decrease response to the spike protein.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/.

1 Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment | Business Wire
2 Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing (yahoo.com)
Post Reply